McKesson (NYSE:MCK) Issues FY 2025 Earnings Guidance

McKesson (NYSE:MCK) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided earnings per share guidance of 32.400-33.000 for the period, compared to the consensus earnings per share estimate of 31.990. The company issued revenue guidance of $355.3 billion-$361.5 billion, compared to the consensus revenue estimate of $351.8 billion.

Wall Street Analysts Forecast Growth

MCK has been the subject of a number of research analyst reports. Barclays upped their price objective on McKesson from $596.00 to $616.00 and gave the stock an “overweight” rating in a report on Thursday, August 8th. Citigroup raised their price objective on McKesson from $630.00 to $713.00 and gave the stock a “buy” rating in a report on Wednesday. Leerink Partners reduced their price objective on McKesson from $665.00 to $630.00 and set an “outperform” rating on the stock in a research note on Monday, October 7th. Mizuho increased their target price on shares of McKesson from $540.00 to $570.00 and gave the stock a “neutral” rating in a research report on Thursday, August 8th. Finally, Baird R W raised shares of McKesson from a “hold” rating to a “strong-buy” rating in a research report on Thursday, November 7th. Two analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, McKesson presently has an average rating of “Moderate Buy” and a consensus target price of $631.57.

McKesson Price Performance

Shares of McKesson stock opened at $606.29 on Friday. McKesson has a 1-year low of $431.35 and a 1-year high of $637.51. The company has a market capitalization of $76.96 billion, a PE ratio of 31.40, a P/E/G ratio of 1.31 and a beta of 0.44. The business has a 50-day moving average of $520.01 and a 200-day moving average of $554.41.

McKesson (NYSE:MCK) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $7.07 earnings per share for the quarter, beating analysts’ consensus estimates of $6.88 by $0.19. McKesson had a negative return on equity of 207.50% and a net margin of 0.77%. The firm had revenue of $93.65 billion during the quarter, compared to analyst estimates of $89.33 billion. During the same quarter last year, the firm earned $6.23 EPS. McKesson’s quarterly revenue was up 21.3% on a year-over-year basis. On average, equities analysts expect that McKesson will post 32.81 earnings per share for the current fiscal year.

McKesson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 2nd. Investors of record on Monday, December 2nd will be issued a $0.71 dividend. The ex-dividend date of this dividend is Monday, December 2nd. This represents a $2.84 annualized dividend and a yield of 0.47%. McKesson’s dividend payout ratio is presently 14.71%.

Insider Buying and Selling at McKesson

In other news, CEO Brian S. Tyler sold 3,753 shares of the business’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $561.10, for a total value of $2,105,808.30. Following the completion of the sale, the chief executive officer now owns 78,586 shares of the company’s stock, valued at approximately $44,094,604.60. The trade was a 4.56 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.11% of the stock is currently owned by insiders.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.